

ANTARES PHARMA, INC.  
Form 10-Q  
May 02, 2019

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D)

OF THE SECURITIES EXCHANGE ACT OF 1934.

For the quarterly period ended March 31, 2019

Commission File Number 1-32302

ANTARES PHARMA, INC.

A Delaware Corporation IRS Employer Identification No. 41-1350192  
100 Princeton South, Suite 300  
Ewing, New Jersey 08628  
(609) 359-3020

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No

Edgar Filing: ANTARES PHARMA, INC. - Form 10-Q

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

|                         |                           |
|-------------------------|---------------------------|
| Large accelerated filer | Accelerated filer         |
| Non-accelerated filer   | Smaller reporting company |
|                         | Emerging growth company   |

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

The number of shares outstanding of the registrant’s Common Stock, \$.01 par value, as of April 30, 2019 was 162,619,811.

Securities registered pursuant to Section 12(b) of the Act:

Trading

| Title of each class | Symbol(s) | Name of each exchange on which registered |
|---------------------|-----------|---|
| Common Stock        | ATRS      | NASDAQ                                    |

ANTARES PHARMA, INC.

INDEX

|  | PAGE |
|--|------|
| PART I. <u>FINANCIAL INFORMATION</u>   | 3    |
| Item 1. <u>Financial Statements</u>  | 3    |
| <u>Consolidated Balance Sheets, as of March 31, 2019 (Unaudited) and December 31, 2018</u>                                       | 3    |
| <u>Consolidated Statements of Operations for the three months ended March 31, 2019 and 2018 (Unaudited)</u>                      | 4    |
| <u>Consolidated Statements of Comprehensive Loss for the three months ended March 31, 2019 and 2018 (Unaudited)</u>              | 5    |
| <u>Consolidated Statements of Changes in Stockholders' Equity for the three months ended March 31, 2019 and 2018 (Unaudited)</u> | 6    |
| <u>Consolidated Statements of Cash Flows for the three months ended March 31, 2019 and 2018 (Unaudited)</u>                      | 7    |
| <u>Notes to Consolidated Financial Statements (Unaudited)</u>  | 8    |
| Item 2. <u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u>                             | 17   |
| Item 3. <u>Quantitative and Qualitative Disclosures About Market Risk</u>  | 23   |
| Item 4. <u>Controls and Procedures</u>   | 23   |
| PART II. <u>OTHER INFORMATION</u>  | 24   |
| Item 1. <u>Legal Proceedings</u>   | 24   |
| Item 1A. <u>Risk Factors</u>   | 24   |
| Item 2. <u>Unregistered Sales of Equity Securities and Use of Proceeds</u>   | 24   |
| Item 3. <u>Default Upon Senior Securities</u>  | 24   |
| Item 4. <u>Mine Safety Disclosures</u>   | 24   |
| Item 5. <u>Other Information</u>   | 24   |

|                         |    |
|-------------------------|----|
| Item 6. <u>Exhibits</u> | 25 |
| <u>SIGNATURES</u>       | 26 |

## PART I – FINANCIAL INFORMATION

Item 1. FINANCIAL STATEMENTS  
ANTARES PHARMA, INC.

## CONSOLIDATED BALANCE SHEETS

(in thousands, except per share amounts)

|   | March 31,<br>2019<br>(Unaudited) | December 31,<br>2018 |
|---|----------------------------------|----------------------|
| <b>Assets</b>   |                                  |                      |
| <b>Current Assets:</b>  |                                  |                      |
| Cash and cash equivalents   | \$ 23,238                        | \$ 27,892            |
| Accounts receivable   | 29,772                           | 18,976               |
| Inventories   | 13,378                           | 11,350               |
| Contract assets   | 9,445                            | 10,442               |
| Prepaid expenses and other current assets   | 3,657                            | 2,648                |
| Total current assets  | 79,490                           | 71,308               |
| Equipment, molds, furniture and fixtures, net   | 15,100                           | 14,895               |
| Right-of-use assets   | 1,910                            | —                    |
| Intangibles, net  | 688                              | 831                  |
| Goodwill  | 1,095                            | 1,095                |
| Other assets  | 502                              | 148                  |
| Total Assets  | \$ 98,785                        | \$ 88,277            |
| <b>Liabilities and Stockholders' Equity</b>   |                                  |                      |
| <b>Current Liabilities:</b>   |                                  |                      |
| Accounts payable  | \$ 15,622                        | \$ 11,135            |
| Accrued expenses and other liabilities  | 11,844                           | 11,997               |
| Long-term debt, current portion   | 4,933                            | 3,043                |
| Lease liabilities, current portion  | 866                              | —                    |
| Deferred revenue  | 1,537                            | 1,018                |
| Total current liabilities   | 34,802                           | 27,193               |
| Long-term debt  | 20,260                           | 22,083               |
| Lease liabilities, long-term  | 1,055                            | —                    |
| Total liabilities   | 56,117                           | 49,276               |
| <b>Stockholders' Equity:</b>  |                                  |                      |
| Preferred Stock: \$0.01 par, authorized 3,000 shares, none outstanding  | —                                | —                    |
| Common Stock: \$0.01 par; 300,000 shares authorized; 162,528 and<br>159,721 issued and outstanding at March 31, 2019 and<br>December 31, 2018, respectively | 1,625                            | 1,597                |
| Additional paid-in capital  | 323,972                          | 314,907              |
| Accumulated deficit   | (282,223 )                       | (276,800 )           |
| Accumulated other comprehensive loss  | (706 )                           | (703 )               |

Edgar Filing: ANTARES PHARMA, INC. - Form 10-Q

|  |           |           |
|--|-----------|-----------|
|  | 42,668    | 39,001    |
| Total Liabilities and Stockholders' Equity | \$ 98,785 | \$ 88,277 |

See accompanying notes to consolidated financial statements.

ANTARES PHARMA, INC.

## CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except per share amounts)

(UNAUDITED)

|  | For the Three<br>Months Ended<br>March 31, |            |
|--|--|------------|
|  | 2019                                       | 2018       |
| <b>Revenue:</b>  |  |            |
| Product sales  | \$18,300                                   | \$10,949   |
| Licensing and development revenue                            | 915  | 1,285      |
| Royalties  | 4,071                                      | 469        |
| Total revenue  | 23,286                                     | 12,703     |
| <b>Cost of revenue:</b>                                      |  |            |
| Cost of product sales  | 10,568                                     | 6,536      |
| Cost of development revenue                                  | 378  | 650        |
| Total cost of revenue  | 10,946                                     | 7,186      |
| Gross profit   | 12,340                                     | 5,517      |
| <b>Operating expenses:</b>                                   |  |            |
| Research and development                                     | 2,387                                      | 2,900      |
| Selling, general and administrative                          | 14,935                                     | 8,236      |
| Total operating expenses                                     | 17,322                                     | 11,136     |
| Operating loss   | (4,982 )                                   | (5,619 )   |
| Interest expense   | (661 )                                     | (631 )     |
| Other income   | 104  | 57         |
| Net loss   | \$(5,539 )                                 | \$(6,193 ) |
| Basic and diluted net loss per common share                  | \$(0.03 )                                  | \$(0.04 )  |
| Basic and diluted weighted average common shares outstanding | 160,446                                    | 156,724    |

See accompanying notes to consolidated financial statements.

ANTARES PHARMA, INC.

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

(in thousands)

(UNAUDITED)

|   | For the Three<br>Months Ended<br>March 31, |           |
|---|--|-----------|
|   | 2019                                       | 2018      |
| Net loss                                | \$(5,539)                                  | \$(6,193) |
| Foreign currency translation adjustment | (3 )                                       | 10        |
| Comprehensive loss                      | \$(5,542)                                  | \$(6,183) |

See accompanying notes to consolidated financial statements.



ANTARES PHARMA, INC.

## CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY

(in thousands)

(UNAUDITED)

|                                   | Three Months Ended March 31, 2019 |          |            |               |             |             |               |
|-----------------------------------|-----------------------------------|----------|------------|---------------|-------------|-------------|---------------|
|                                   | Common Stock                      |          |            | Additional    |             | Accumulated | Total         |
|                                   | Shares                            | Amount   | Capital    | Paid-In       | Accumulated | Other       |               |
|                                   |                                   |          |            |               |             | Deficit     | Comprehensive |
|                                   |                                   |          |            |               | Loss        | Equity      |               |
| December 31, 2018                 | 159,721                           | \$ 1,597 | \$ 314,907 | \$ (276,800 ) | \$ (703 )   | \$ 39,001   |               |
| Issuance of common stock          | 2,307                             | 23       | 7,762      | —             | —           | 7,785       |               |
| Common stock issued under equity  |                                   |          |            |               |             |             |               |
| compensation plan, net of         |                                   |          |            |               |             |             |               |
| shares withheld for taxes         | 288                               | 3        | (411 )     | —             | —           | (408 )      |               |
| Exercise of options               | 212                               | 2        | 348        | —             | —           | 350         |               |
| Share-based compensation          | —                                 | —        | 1,366      | —             | —           | 1,366       |               |
| Cumulative effect of change in    |                                   |          |            |               |             |             |               |
| accounting principle              | —                                 | —        | —          | 116           | —           | 116         |               |
| Net loss                          | —                                 | —        | —          | (5,539 )      | —           | (5,539 )    |               |
| Other comprehensive income (loss) | —                                 | —        | —          | —             | (3 )        | (3 )        |               |
| March 31, 2019                    | 162,528                           | \$ 1,625 | \$ 323,972 | \$ (282,223 ) | \$ (706 )   | \$ 42,668   |               |

|                                  | Three Months Ended March 31, 2018 |          |            |               |             |             |               |
|----------------------------------|-----------------------------------|----------|------------|---------------|-------------|-------------|---------------|
|                                  | Common Stock                      |          |            | Additional    |             | Accumulated | Total         |
|                                  | Shares                            | Amount   | Capital    | Paid-In       | Accumulated | Other       |               |
|                                  |                                   |          |            |               |             | Deficit     | Comprehensive |
|                                  |                                   |          |            |               | Loss        | Equity      |               |
| December 31, 2017                | 156,675                           | \$ 1,567 | \$ 302,965 | \$ (270,285 ) | \$ (700 )   | \$ 33,547   |               |
| Common stock issued under equity |                                   |          |            |               |             |             |               |
| compensation plan, net of        |                                   |          |            |               |             |             |               |
| shares withheld for taxes        | 114                               | 1        | (131 )     | —             | —           | (130 )      |               |
| Exercise of options              | 32                                | —        | 28         | —             | —           | 28          |               |
| Share-based compensation         | —                                 | —        | 985        | —             | —           | 985         |               |
| Net loss                         | —                                 | —        | —          | (6,193 )      | —           | (6,193 )    |               |

Edgar Filing: ANTARES PHARMA, INC. - Form 10-Q

|                                   |         |          |            |             |           |             |    |
|-----------------------------------|---------|----------|------------|-------------|-----------|-------------|----|
| Other comprehensive income (loss) | —       | —        | —          |             |           | 10          | 10 |
| March 31, 2018                    | 156,821 | \$ 1,568 | \$ 303,847 | \$ (276,478 | ) \$ (690 | ) \$ 28,247 |    |

See accompanying notes to consolidated financial statements.

ANTARES PHARMA, INC.

## CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

(UNAUDITED)

|   | Three Months<br>Ended<br>March 31, |            |
|---|------------------------------------|------------|
|   | 2019                               | 2018       |
| <b>Cash flows from operating activities:</b>  |                                    |            |
| Net loss  | \$(5,539 )                         | \$(6,193 ) |
| <b>Adjustments to reconcile net loss to net cash used in operating activities:</b>        |                                    |            |
| Stock-based compensation expense  | 1,366                              | 985        |
| Depreciation and amortization   | 678                                | 604        |
| Other   | 67                                 | 63         |
| <b>Changes in operating assets and liabilities:</b>                                       |                                    |            |
| Accounts receivable   | (10,799)                           | (608 )     |
| Inventories   | (2,028 )                           | (655 )     |
| Prepaid expenses and other assets   | (1,364 )                           | 250        |
| Contract assets   | 997                                | 73         |
| Accounts payable  | 4,137                              | 550        |
| Accrued expenses and other current liabilities  | (25 )                              | (99 )      |
| Deferred revenue  | 520                                | (999 )     |
| Net cash used in operating activities   | (11,990)                           | (6,029 )   |
| <b>Cash flows from investing activities:</b>  |                                    |            |
| Proceeds from sale of assets  | —                                  | 2,750      |
| Purchases of equipment, molds, furniture and fixtures                                     | (391 )                             | (61 )      |
| Additions to patent rights  | —                                  | (10 )      |
| Net cash (used in) provided by investing activities                                       | (391 )                             | 2,679      |
| <b>Cash flows from financing activities:</b>  |                                    |            |
| Proceeds from issuance of common stock, net   | 7,785                              | —          |
| Proceeds from exercise of stock options   | 350                                | 28         |
| Taxes paid related to net share settlement of equity awards                               | (408 )                             | (130 )     |
| Net cash provided by (used in) financing activities                                       | 7,727                              | (102 )     |
| Effect of exchange rate changes on cash   | —                                  | 1          |
| Net decrease in cash and cash equivalents   | (4,654 )                           | (3,451 )   |
| <b>Cash and cash equivalents:</b>   |                                    |            |
| Beginning of period   | 27,892                             | 26,562     |
| End of period   | \$23,238                           | \$23,111   |
| <b>Supplemental disclosure of non-cash investing activities:</b>                          |                                    |            |
| <b>Purchases of equipment, molds, furniture and fixtures recorded in accounts payable</b> |                                    |            |
| and accrued expenses  | \$399                              | \$173      |
| Additions to patent rights recorded in accounts payable and accrued expenses              | \$—                                | \$6        |

See accompanying notes to consolidated financial statements.

7

---

ANTARES PHARMA, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share amounts)

(UNAUDITED)

1. Description of Business

Antares Pharma, Inc. (“Antares” or the “Company”) is a combination drug device company focused primarily on the development and commercialization of self-administered parenteral pharmaceutical products and technologies. The Company develops and commercializes, for itself or with partners, novel therapeutic products using its advanced drug delivery technology to enhance existing drug compounds and delivery methods. The Company’s intramuscular and subcutaneous injection technology platforms include the VIBEX<sup>®</sup> and VIBEX<sup>®</sup> QuickShot<sup>®</sup> pressure-assisted auto injector systems suitable for branded and generic injectable drugs in unit dose containers and disposable multi-dose pen injectors. The Company has a portfolio of proprietary and partnered commercial products and ongoing product development programs in various stages of development. The Company has formed significant strategic alliances with Teva Pharmaceutical Industries, Ltd. (“Teva”), AMAG Pharmaceuticals, Inc. (“AMAG”) and Pfizer Inc. (“Pfizer”).

The Company developed and commercialized XYOSTED<sup>™</sup> (testosterone enanthate) injection, indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone, which was approved by the U.S. Food and Drug Administration (“FDA”) on September 28, 2018 and launched for commercial sale in November 2018. XYOSTED<sup>™</sup> is the only FDA-approved subcutaneous testosterone enanthate product for once-weekly, at-home self-administration.

The Company also markets and sells its proprietary product OTREXUP<sup>®</sup> (methotrexate) injection in the U.S., which is indicated for adults with severe active rheumatoid arthritis, children with active polyarticular juvenile idiopathic arthritis and adults with severe recalcitrant psoriasis, and was launched for commercial sale in February 2014.

Through its commercialization partner Teva, the Company sells Sumatriptan Injection USP, indicated in the U.S. for the acute treatment of migraine and cluster headache in adults. Sumatriptan Injection USP was launched for commercial sale in June 2016.

In collaboration with AMAG, the Company developed a subcutaneous auto injector for use with AMAG’s progestin hormone drug Makena<sup>®</sup> (hydroxyprogesterone caproate injection) under an exclusive license and development agreement. In February 2018, the FDA approved AMAG’s supplemental New Drug Application (“sNDA”) for the Makena<sup>®</sup> subcutaneous auto injector drug-device combination product, which is a ready-to-administer treatment indicated to reduce the risk of preterm birth in women pregnant with one baby and who spontaneously delivered one preterm baby in the past. The Company is the exclusive supplier of the devices and final assembled and packaged commercial product. AMAG launched the product for commercial sale in the first quarter of 2018.

Through a license, development and supply agreement with Teva, Antares developed and is the exclusive supplier of the device for Teva’s Epinephrine Injection USP, which is indicated for emergency treatment of severe allergic reactions in adults and certain pediatric patients. The product was approved by the FDA in August 2018 and launched for commercial sale in late fourth quarter of 2018.

The Company is also developing two multi-dose pen injector products in collaboration with Teva, a combination drug device rescue pen in collaboration with Pfizer, and has other ongoing internal research and development programs.

## 2. Basis of Presentation and Significant Accounting Policies

The accompanying unaudited consolidated financial statements have been prepared in accordance with generally accepted accounting principles ("GAAP") in the U.S. for interim financial information and with the instructions to Form 10-Q and Article 10 of the Securities and Exchange Commission's Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the U.S. for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. The accompanying consolidated financial statements and notes thereto should be read in conjunction with the Company's Annual Report on Form 10-K for the year ended December 31, 2018. Operating results for the three months ended March 31, 2019 are not necessarily indicative of the results that may be expected for the year ending December 31, 2019.

ANTARES PHARMA, INC.

## NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share amounts)

(UNAUDITED)

## Revisions of Prior Period Financial Statements

During the preparation of the consolidated financial statements for the year ended December 31, 2018, management revised the presentation of certain regulatory fees between research and development expenses and selling, general and administrative expenses. As a result, the Company also made revisions to its prior period interim consolidated statements of operations as follows:

|  | Three<br>months<br>ended<br>March 31,<br>2018 |
|--|---|
| Research and development, as reported            | \$ 3,320                                      |
| Research and development, as revised             | 2,900   |
| Selling, general and administrative, as reported | 7,816   |
| Selling, general and administrative, as revised  | 8,236   |

These revisions had no impact on the Company's total operating expenses or net loss. The revisions also had no impact on the consolidated balance sheets or the consolidated statements of comprehensive loss, stockholders' equity or cash flows. Management evaluated the materiality of the revisions from a quantitative and qualitative perspective and concluded that the revisions are immaterial to the consolidated financial statements.

## Accounting Pronouncements Recently Adopted

The Company adopted Financial Accounting Standards Board ("FASB") Accounting Standards Update ("ASU") No. 2016-02 Leases ("Topic 842") effective January 1, 2019, electing the package of practical expedients and applying the transition provisions as of the effective date. Reporting periods beginning on or after January 1, 2019 are presented under Topic 842, while prior period amounts, as reported under previous GAAP, were not adjusted. As a result of the adoption of Topic 842, the Company recognized approximately \$1.0 million in right-of-use assets and lease liabilities in connection with its existing operating leases, with a cumulative effect adjustment of \$0.1 million to accumulated deficit as of January 1, 2019. The adoption of Topic 842 on January 1, 2019 did not have a significant impact on the Company's consolidated results of operations or cash flows.

## Recent Accounting Pronouncements Not Yet Adopted

In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments. The amendment in this update replaces the incurred loss impairment methodology in current GAAP with a methodology that reflects expected credit losses on instruments within its scope, including trade receivables. This update is intended to provide financial statement users with more decision-useful information about the expected credit losses. This ASU is effective for annual periods and interim periods for those

annual periods beginning after December 15, 2019. The Company is currently evaluating the impact the adoption of ASU 2016-13 will have on its consolidated financial statements.

### Inventories

Inventories are stated at the lower of cost or net realizable value. Cost is determined on a first-in, first-out basis. Certain components of the Company's products are provided by a limited number of vendors, and the Company's production, assembly, warehousing and distribution operations are outsourced to third-parties where substantially all of the Company's inventory is located. Disruption of supply from key vendors or third-party suppliers may have a material adverse impact on the Company's operations. The Company provides a reserve for potentially excess, dated or obsolete inventories based on an analysis of inventory on hand compared to forecasts of future sales, which was \$1,088 and \$847 at March 31, 2019 and December 31, 2018, respectively. Inventories consist of the following:

|                     | March 31,<br>2019 | December 31,<br>2018 |
|---------------------|-------------------|----------------------|
| <b>Inventories:</b> |                   |                      |
| Raw material        | \$ 26             | \$ 26                |
| Work in process     | 7,713             | 7,622                |
| Finished goods      | 5,639             | 3,702                |
|                     | <b>\$ 13,378</b>  | <b>\$ 11,350</b>     |



ANTARES PHARMA, INC.

## NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share amounts)

(UNAUDITED)

## Equipment, Molds, Furniture, and Fixtures

Equipment, molds, furniture, and fixtures are stated at cost, net of accumulated depreciation, and are depreciated using the straight-line method over their estimated useful lives ranging from three to ten years. As of March 31, 2019 and December 31, 2018, the Company's equipment, molds, furniture and fixtures totaled \$15,100 and \$14,895, respectively, which is presented net of accumulated depreciation of \$8,106 and \$7,570 as of March 31, 2019 and December 31, 2018, respectively.

## Leases

The Company recognizes right-of-use ("ROU") assets and lease liabilities when it obtains the right to control an asset under a leasing arrangement with an initial term greater than twelve months. The Company leases its facilities under non-cancellable operating leases and, beginning in the first quarter of 2019, entered into a master lease arrangement for a fleet of vehicles for use by its sales force. All of the Company's leasing arrangements are classified as operating leases with remaining lease terms of seven months to three years.

The Company evaluates the nature of each lease at the inception of an arrangement to determine whether it is an operating or financing lease and recognizes the right-of-use asset and lease liabilities based on the present value of future minimum lease payments over the expected lease term. The Company's leases do not generally contain an implicit interest rate and therefore the Company uses the incremental borrowing rate it would expect to pay to borrow on a similar collateralized basis over a similar term in order to determine the present value of its lease payments. Each of the Company's lease arrangements contain renewal options that have not been included in the determination of the lease term, as they are not reasonably certain of exercise. For contracts that contain lease and non-lease components, the Company accounts for both components as a single lease component. Variable lease payments are expensed as incurred.

Operating lease costs were \$175 for the three months ended March 31, 2019. Cash paid for amounts included in the measurement of operating lease liabilities was \$178 for the three months ended March 31, 2019. During the three months ended March 31, 2019, operating lease ROU assets obtained in exchange for operating lease obligations were \$1,074. As of March 31, 2019, the weighted average discount rate was approximately 9.5% and the weighted average remaining lease term was 2.7 years. The following table summarizes the Company's operating lease maturities as of March 31, 2019:

|                                | Amount |
|--------------------------------|--------|
| 2019                           | \$ 797 |
| 2020                           | 515    |
| 2021                           | 549    |
| 2022                           | 162    |
| Total remaining lease payments | 2,023  |

|                         |          |
|-------------------------|----------|
| Less: imputed interest  | (102 )   |
| Total lease liabilities | \$ 1,921 |

#### Revenue Recognition

The Company generates revenue from proprietary and partnered product sales, license and development activities and royalty arrangements. Revenue is recognized when or as the Company transfers control of the promised goods or services to its customers at the transaction price, which is the amount that reflects the consideration to which it expects to be entitled to in exchange for those goods or services.

At inception of each contract, the Company identifies the goods and services that have been promised to the customer and each of those that represent a distinct performance obligation, determines the transaction price including any variable consideration, allocates the transaction price to the distinct performance obligations and determines whether control transfers to the customer at a point in time or over time. Variable consideration is included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. The Company reassesses its reserves for variable consideration at each reporting date and makes adjustments, if necessary, which may affect revenue and earnings in periods in which any such changes become known.

ANTARES PHARMA, INC.

## NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share amounts)

(UNAUDITED)

The Company has elected to recognize the cost for freight and shipping activities as fulfillment cost. Amounts billed to customers for shipping and handling are included as part of the transaction price and recognized as revenue when control of underlying goods are transferred to the customer. The related shipping and freight charges incurred by the Company are included in cost of revenue.

### Proprietary Product Sales

The Company sells its proprietary products OTREXUP® and XYOSTED™ primarily to wholesale and specialty distributors. Revenue is recognized when control has transferred to the customer, which is typically upon delivery, at the net selling price, which reflects the variable consideration for which reserves and sales allowances are established for estimated returns, wholesale distribution fees, prompt payment discounts, government rebates and chargebacks, plan rebate arrangements and patient discount and support programs.

The determination of certain of these reserves and sales allowances require management to make a number of judgements and estimates to reflect the Company's best estimate of the transaction price and the amount of consideration to which it believes it is ultimately entitled to receive. The expected value is determined based on unit sales data, contractual terms with customers and third-party payers, historical and expected utilization rates, any new or anticipated changes in programs or regulations that would impact the amount of the actual rebates, customer purchasing patterns, product expiration dates and levels of inventory in the distribution channel. Reserves for prompt payment discounts are recorded as a reduction in accounts receivable. Reserves for returns, rebates and chargebacks, distributor fees and customer co-pay support programs are included within current liabilities in the consolidated balance sheets.

### Partnered Product Sales

The Company is party to several license, development, supply and distribution arrangements with pharmaceutical partners, under which the Company produces and is the exclusive supplier of certain products, devices and/or components. Revenue is recognized when or as control of the goods transfers to the customer as follows:

The Company is the exclusive supplier of the Makena® subcutaneous auto injector product to AMAG. Because the product is custom manufactured for AMAG with no alternative use and the Company has a contractual right to payment for performance completed to date, control is continuously transferred to the customer as product is produced pursuant to firm purchase orders. Revenue is recognized over time using the output method based on the contractual selling price and number of units produced. The amount of revenue recognized in excess of the amount shipped/billed to the customer, if any, is recorded as contract assets due to the short-term nature in which the amount is ultimately expected to be billed and collected from the customer.

All other partnered product sales are recognized at the point in time in which control is transferred to the customer, which is typically upon shipment. Sales terms and pricing are governed by the respective supply and distribution agreements, and there is generally no price protection or right of return. Revenue is recognized at the transaction price, which includes the contractual per unit selling price and estimated variable consideration, if any. For example, the

Company sells Sumatriptan Injection USP to Teva at cost and is entitled to receive 50 percent of the net profits from commercial sales made by Teva, payable to the Company within 45 days after the end of the quarter in which the commercial sales are made. The Company recognizes revenue, including the estimated variable consideration it expects to receive for contract margin on future commercial sales, upon shipment of the goods to Teva. The estimated variable consideration is recognized at an amount the Company believes is not subject to significant reversal based on historical experience, and is adjusted at each reporting period if the most likely amount of expected consideration changes or becomes fixed.

#### Licensing and Development Revenue

The Company has entered into several license, development and supply arrangements with pharmaceutical partners under which the Company grants a license to its device technology and know-how and provides research and development services that often involve multiple performance obligations and highly customized deliverables. For such arrangements, the Company identifies each of the promised goods and services within the contract and the distinct performance obligations at inception, and allocates consideration to each performance obligation based on relative standalone selling price, which is generally determined based on the expected cost plus margin.

ANTARES PHARMA, INC.

## NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share amounts)

(UNAUDITED)

If the contract includes an enforceable right to payment for performance completed to date and performance obligations are satisfied over time, the Company recognized revenue over the development period using either the input or output method depending on which is most appropriate given the nature of the distinct deliverable. For other contracts that do not contain an enforceable right to payment for performance completed to date, revenue is recognized when control is transferred to the customer. Factors that may indicate that the transfer of control has occurred include the transfer of legal title, transfer of physical possession, the customer has obtained the significant risks and rewards of ownership of the assets and the Company has a present right to payment.

The Company's typical payment terms for development contracts may include an upfront payment equal to a percentage of the total contract value with the remaining portion to be billed upon completion and transfer of the individual deliverables or satisfaction of the individual performance obligations. The Company records a liability for cash received in advance of performance, which is presented within deferred revenue on the consolidated balance sheet and recognized as revenue when the associated performance obligations have been satisfied.

License fees and milestones received in exchange for the grant of a license to the Company's functional intellectual property ("IP") such as patented technology and know-how in connection with a partnered development arrangement are generally recognized at inception of the arrangement, or over the development period depending on the facts and circumstances, as the license is not generally distinct from the non-licensed goods or services to be provided under the contract. Milestone payments that are contingent upon the occurrence of future events, are evaluated and recorded at the most likely amount, and to the extent that it is probable that a significant reversal will not occur when the associated uncertainty is resolved.

### Royalties

The Company earns royalties in connection with licenses granted under license and development arrangements with partners. Royalties are based upon a percentage of commercial sales of partnered products with rates ranging from mid single digit to low double digit and are tiered based on levels of net sales. These sales-based royalties, for which the license was deemed the predominant element to which the royalties relate, are estimated and recognized in the period in which the partners' commercial sales occur. The royalties are generally reported and payable to the Company within 45 to 60 days of the end of the period in which the commercial sales are made. The Company bases its estimates of royalties earned on actual sales information from its partners when available or estimated prescription sales from external sources and estimated net selling price. If actual royalties received are different than amounts estimated, the Company would adjust the royalty revenue in the period in which the adjustment becomes known.

### Remaining Performance Obligations

Remaining performance obligations represents the allocation of transaction price of firm orders and development contract deliverables for which work has not been completed or orders fulfilled, and excludes potential purchase orders under ordering-type supply contracts with indefinite delivery or quantity. As of March 31, 2019, the aggregate value of remaining performance obligations, excluding contracts with an original expected length of one year or less, was \$4.8 million. The Company expects to recognize revenue on the remaining performance obligations over the next

2.5 years.

### 3. Stockholders' Equity

The Company has a sales agreement (the "Sales Agreement") with Cowen and Company, LLC ("Cowen") under which the Company may offer and sell, from time to time and at its sole discretion, shares of its common stock having an aggregate offering price of up to \$30.0 million through Cowen as the Company's sales agent and/or as principal. Cowen may sell the common stock by any method permitted by law deemed to be an "at the market offering" as defined in Rule 415 of the Securities Act of 1933, as amended (the "Offering".) The Company pays a commission of 3.0% of the gross sales proceeds of any common stock sold through Cowen under the Sales Agreement.

During the three months ended March 31, 2019, the Company sold 2.3 million shares of common stock pursuant to the Offering and Sales Agreement. The sale of common stock resulted in aggregate gross proceeds of \$8.1 million, less sales commission and payment of offering costs, resulting in net offering proceeds to the Company of \$7.8 million. No sales of common stock were made in the period ended March 31, 2018. The net proceeds are intended to be used for general corporate purposes including, but not limited to, product commercialization, research and development projects, funding of clinical trials, capital expenditures and working capital.

12

---

ANTARES PHARMA, INC.

## NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share amounts)

(UNAUDITED)

## 4. Share-Based Compensation

The Company's 2008 Equity Compensation Plan, as amended and restated (the "Plan") allows for grants in the form of incentive stock options, nonqualified stock options, stock units, stock awards, stock appreciation rights, and other stock-based awards. All of the Company's officers, directors, employees, consultants and advisors are eligible to receive grants under the Plan. The maximum number of shares authorized for issuance under the Plan is 32,200 and the maximum number of shares of stock that may be granted to any one employee for qualified performance-based compensation during a calendar year is 4,000 shares. Options to purchase shares of common stock are granted at exercise prices not less than 100% of fair market value on the dates of grant. The term of each option is ten years and the options typically vest in quarterly installments over a three-year period with a minimum vesting period of one year. As of March 31, 2019, the Plan had approximately 3,148 shares available for grant. Stock option exercises are satisfied through the issuance of new shares.

## Stock Options

The following is a summary of stock option activity under the Plan as of and for the three months ended March 31, 2019:

|                                  | Number<br>of<br>Shares | Weighted<br>Average<br>Exercise<br>Price | Weighted<br>Average<br>Remaining<br>Contractual<br>Term<br>(Years) | Aggregate<br>Intrinsic<br>Value |
|----------------------------------|------------------------|--|--|---------------------------------|
| Outstanding at December 31, 2018 | 14,079                 | \$ 2.19                                  |  |                                 |
| Granted                          | 20                     | 3.72                                     |  |                                 |
| Exercised                        | (212 )                 | 1.65                                     |  |                                 |
| Cancelled/Forfeited              | (30 )                  | 2.95                                     |  |                                 |
| Outstanding at March 31, 2019    | 13,857                 | 2.20                                     | 6.4  | \$ 12,048                       |
| Exercisable at March 31, 2019    | 11,025                 | \$ 2.09                                  | 5.8  | \$ 10,853                       |

During the three months ended March 31, 2019, stock option exercises resulted in cash proceeds to the Company of \$350 and the issuance of 212 shares of common stock. Stock option exercises resulted in proceeds of \$28 and the issuance of 32 shares of common stock in the three months ended March 31, 2018. The Company recognized \$908 and \$661 of compensation expense related to stock options for the three months ended March 31, 2019 and 2018, respectively.

## Long Term Incentive Program

The Company's Board of Directors has approved a long-term incentive program ("LTIP") for the benefit of the Company's senior executives. Pursuant to the LTIP, the Company's senior executives have been awarded stock options, restricted stock units ("RSUs") and performance stock units ("PSUs") with targeted values based on values granted to similarly situated senior executives in the Company's peer group. The stock options have a ten-year term, have an exercise price equal to the closing price of the Company's common stock on the date of grant, vest in quarterly installments over three years, were otherwise granted on the same standard terms and conditions as other stock options granted pursuant to the Plan and are included in the stock options table above. The RSUs vest in three equal annual installments. The PSU awards made to senior executives vest and convert into shares of the Company's common stock based on the Company's attainment of certain performance goals as established by the Company's Board of Directors over a performance period, which is typically three years.



ANTARES PHARMA, INC.

## NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share amounts)

(UNAUDITED)

The non-vested PSU awards and RSU awards granted under the long-term incentive program are summarized in the following table:

|                                  | Performance Stock<br>Units |  | Restricted Stock Units |  |
|----------------------------------|----------------------------|--|------------------------|--|
|                                  | Number<br>of               | Weighted<br>Average Grant<br>Date Fair | Number<br>of           | Weighted<br>Average Grant<br>Date Fair |
|                                  | Shares                     | Value                                  | Shares                 | Value                                  |
| Outstanding at December 31, 2018 | 1,842                      | \$ 2.41                                | 1,226                  | \$ 2.44                                |
| Granted                          | —                          | —                                      | —                      | —                                      |
| Vested/settled                   | (415 )                     | 1.18                                   | —                      | —                                      |
| Forfeited/expired                | (178 )                     | 1.12                                   | —                      | —                                      |
| Outstanding at March 31, 2019    | 1,249                      | \$ 3.01                                | 1,226                  | \$ 2.44                                |

In connection with PSU awards, the Company recognized compensation expense of \$127 and \$79 for the three months ended March 31, 2019 and 2018, respectively. Compensation expense recognized in connection with RSU awards was \$331 and \$245 for the three months ended March 31, 2019 and 2018, respectively.

The LTIP awards that vested during the three months ended March 31, 2019 and 2018 were net-share settled such that the Company withheld shares with a value equivalent to the employees' tax obligations for applicable income and other employment taxes, and remitted the cash to the appropriate taxing authorities. The Company withheld 127 and 59 shares during the three months ended March 31, 2019 and 2018, respectively, to satisfy tax obligations, which was determined based on the fair value of the shares on their vesting date equal to the Company's closing stock price on such date. Total payments for the employees' tax obligations to the taxing authorities were \$408 and \$130 for the three months ended March 31, 2019 and 2018, respectively, and are reflected as a cash outflow from financing activities within the consolidated statements of cash flows. Net-share settlements have the effect of share repurchases by the Company as they reduce the number of shares that would have otherwise been issued as a result of the vesting.

## 5. Revenues, Significant Customers and Concentrations of Risk

The following table presents the Company's revenue on a disaggregated basis by types of goods and services and major product lines:

|                                   | Three months<br>ended March 31, |          |
|-----------------------------------|---------------------------------|----------|
|                                   | 2019                            | 2018     |
| Proprietary product sales         | \$4,771                         | \$3,971  |
| Partnered product sales           | 13,529                          | 6,978    |
| Total product revenue             | 18,300                          | 10,949   |
| Licensing and development revenue | 915                             | 1,285    |
| Royalties                         | 4,071                           | 469      |
| Total revenue                     | \$23,286                        | \$12,703 |

Revenues disaggregated by customer location are as follows:

|                          | Three Months<br>Ended<br>March 31, |          |
|--------------------------|------------------------------------|----------|
|                          | 2019                               | 2018     |
| United States of America | \$21,185                           | \$11,201 |
| Europe                   | 2,090                              | 1,419    |
| Other                    | 11                                 | 83       |
|                          | \$23,286                           | \$12,703 |

ANTARES PHARMA, INC.

## NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share amounts)

(UNAUDITED)

Significant customers from which the Company derived 10% or more of its total revenue in any of the periods presented are as follows:

|                   | Three Months<br>Ended<br>March 31, |         |
|-------------------|------------------------------------|---------|
|                   | 2019                               | 2018    |
| Teva              | \$10,611                           | \$4,167 |
| AMAG              | 4,592                              | 2,834   |
| McKesson          | 1,247                              | 1,843   |
| AmerisourceBergen | 1,581                              | 1,423   |
| Ferring           | 3,096                              | 1,474   |

## 6. Net Loss Per Share

Basic loss per common share is computed by dividing net loss applicable to common stockholders by the weighted-average number of common shares outstanding for the period. Diluted loss per common share reflects the potential dilution from the exercise or conversion of securities into common stock. Potentially dilutive stock options and other share-based awards excluded from dilutive loss per share because their effect was anti-dilutive totaled 16,332 and 14,481 at March 31, 2019 and 2018, respectively.

## 7. Commitments and Contingencies

## Pending Litigation

On October 23, 2017, Randy Smith filed a complaint in the District of New Jersey, captioned Randy Smith, Individually and on Behalf of All Others Similarly Situated v. Antares Pharma, Inc., Robert F. Apple and Fred M. Powell (“Smith”), Case No. 3:17-cv-08945-MAS-DEA, on behalf of a putative class of persons who purchased or otherwise acquired Antares securities between December 21, 2016 and October 12, 2017, inclusive, asserting claims for purported violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, against Antares, Robert F. Apple and Fred M. Powell. The Smith complaint contends that defendants made false and/or misleading statements and/or failed to disclose that: (i) Antares had provided insufficient data to the FDA in connection with the NDA for XYOSTED™; and (ii) accordingly, Antares had overstated the approval prospects for XYOSTED™. On July 27, 2018, the court entered an order appointing Serghei Lungu as lead plaintiff, Pomerantz LLP as lead counsel, and Lite DePalma Greenberg, LLC as liaison counsel for plaintiff. On August 3, 2018, the parties submitted a stipulation and proposed order, setting forth an agreed-upon schedule for responding to the

complaint, which the court granted. Pursuant to that order, plaintiff filed a Consolidated Amended Class Action Complaint on October 9, 2018. On November 26, 2018, defendants filed a motion to dismiss. Plaintiff filed an opposition to the motion on January 10, 2019 and defendants filed a reply in support of their motion on February 25, 2019. The Company believes that the claims in the Smith action lack merit and intends to defend them vigorously.

On January 12, 2018, a stockholder of the Company filed a derivative civil action, captioned Chiru Mackert, derivatively on behalf of Antares Pharma, Inc., v. Robert F. Apple, et al. (“Mackert”), in the Superior Court of New Jersey Chancery Division, Mercer County (Case No. C-000011-18). On January 17, 2018, another stockholder filed a derivative action in the same court, captioned Vikram Rao, Derivatively on Behalf of Antares Pharma, Inc. v. Robert F. Apple, et al. (“Rao”) (Case No. C-000004-18). Both complaints name Robert F. Apple, Fred M. Powell, Thomas J. Garrity, Jacques Gonella, Anton Gueth, Leonard S. Jacob, Marvin Samson and Robert P. Roche, Jr. as defendants, and the Company as nominal defendant, and they assert claims for breach of fiduciary duties, unjust enrichment, abuse of control, gross mismanagement, and waste of corporate assets arising from the same facts underlying the Smith securities class action. The plaintiffs seek damages, corporate governance and internal procedure reforms and improvements, restitution, reasonable attorneys’ fees, experts’ fees, costs, and expenses. The parties have filed a stipulation consolidating the two actions and staying the proceedings pending the court’s decision on defendants’ motion to dismiss the Smith action.

ANTARES PHARMA, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share amounts)

(UNAUDITED)

On January 17, 2018, a stockholder of the Company filed a derivative civil action, captioned Robert Clark, Derivatively on Behalf of Antares Pharma, Inc. v. Robert F. Apple, et al. (“Clark”) (Case No. 3:18-cv-00703-MAS-DEA), against Robert F. Apple, Thomas J. Garrity, Jacques Gonella, Leonard S. Jacob, Marvin Samson, Anton G. Gueth and Robert P. Roche, Jr. as defendants, and Company as a nominal defendant. The action was filed in the U.S. District Court for the District of New Jersey and asserts claims for breach of fiduciary duties, unjust enrichment, abuse of control, waste of corporate assets, and a violation of Section 14(a) of the Securities Exchange Act of 1934. This complaint relates to the same facts underlying the Smith securities class action and the other derivative actions. The plaintiff in Clark seeks damages, corporate governance and internal procedure reforms and improvements, reasonable attorneys’ fees, accountants’ and experts’ fees, costs, and expenses. The parties have filed a stipulation staying the action pending the court’s decision on defendants’ motion to dismiss the Smith action.

## Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

### Forward-Looking Statements

Certain statements in this report, including statements in the management's discussion and analysis section set forth below, may be considered "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that involve risks and uncertainties. Forward-looking statements can be identified by the words "expect," "estimate," "plan," "project," "anticipate," "should," "intend," "may," "will," "believe," "continue" or other words and terms of similar meaning in connection with any discussion of, among other things, future operating or financial performance, strategic initiatives and business strategies, regulatory or competitive environments, our intellectual property and product development. In particular, these forward-looking statements include, among others, statements about:

- our expectations regarding the commercialization of XYOSTED™ (testosterone enanthate) injection for testosterone replacement therapy, including marketing and reimbursement strategies, and future revenues related thereto;
- our expectations regarding continued sales of OTREXUP® (methotrexate) injection;
- our expectations regarding sales of Sumatriptan Injection USP to our partner, Teva Pharmaceutical Industries, Ltd. ("Teva"), and Teva's ability to successfully distribute and sell Sumatriptan Injection USP;
- our expectations regarding the ability of our partner, AMAG Pharmaceuticals, Inc. ("AMAG"), to continue to successfully commercialize the Makena® subcutaneous auto injector, and any future revenue related thereto;
- our expectations regarding the ability of our partner, Teva, to successfully commercialize the generically equivalent version of Mylan's EpiPen® ("generic epinephrine injection"), and any future revenue related thereto;
- our expectations regarding continued product development with Teva of the teriparatide disposable pen injector and exenatide disposable pen injector, and Teva's ability to obtain FDA approval and AB-rating for each of those products;
- our plans to develop a rescue pen for an undisclosed drug with our partner Pfizer, Inc. ("Pfizer") and our intention to enter into a separate supply agreement with Pfizer;
- our expectations about the timing and successful completion of the sale of our worldwide rights, including the completion of outstanding purchase orders, for the ZOMAJET™ needle-free auto injector device product line to Ferring International Center S.A. (together with Ferring Pharmaceuticals Inc. and Ferring B.V. individually and collectively referred to as "Ferring");
- our expectations about the timing and outcome of pending or potential claims and litigation, including without limitation, the pending securities class action and derivative actions;
- our expectations regarding trends in pharmaceutical drug delivery characteristics;
- our anticipated continued reliance on contract manufacturers to manufacture our products;
- our anticipated continued reliance on third parties to provide certain services for our products including logistics, warehousing, distribution, invoicing, contract administration and chargeback processing;
- our sales and marketing plans;
- timing and results of our research and development projects, including clinical trials, and our anticipated continued reliance on third parties in conducting studies, trials and other research and development activities;
- our expectations about our future revenues, including our ability to achieve the 2019 revenue guidance, cash flows and our ability to support our operations;
- our estimates and expectations regarding the sufficiency of our cash resources, anticipated capital requirements and our need for and ability to obtain additional financing;
- our expectations and estimates with regard to current accounting practices and the potential impact of new accounting pronouncements and tax legislation;
- our expectations regarding our financial and operating results for the year ending December 31, 2019; and

- other statements regarding matters that are not historical facts or statements of current condition.

Forward-looking statements are based on assumptions that we have made in light of our industry experience as well as our perceptions of historical trends, current conditions, expected future developments and other factors we believe are appropriate under the circumstances. As you read and consider this report, you should understand that these statements are not guarantees of

performance results. Forward-looking statements involve known and unknown risks, uncertainties and assumptions, and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. While we believe that we have a reasonable basis for each forward-looking statement contained in this report, we caution you that these statements are based on a combination of facts and factors currently known by us and projections of the future about which we cannot be certain. Many factors may affect our ability to achieve our objectives, including:

- unsuccessful marketing and commercialization efforts by us or our partners;
- interruptions in supply or an inability to adequately manage third party contract manufacturers to meet customer supply requirements;
- our inability to obtain or maintain adequate third-party payer coverage of marketed products;
- the timing and results of our or our partners' research projects or clinical trials of product candidates in development including projects with Teva and Pfizer;
- actions by the FDA or other regulatory agencies with respect to our products or product candidates of our partners;
- our inability to generate continued growth in product, product development, licensing and royalties;
- the lack of market acceptance of our and our partners' products and future revenues from these products;
- a decrease in business from our major customers and partners;
- our inability to compete successfully against new and existing competitors or to leverage our research and development capabilities or our marketing capabilities;
- our inability to establish and maintain our sales and marketing capability, our inability to effectively market our services or obtain and maintain arrangements with our customers, payors, partners and manufacturers;
- changes or delays in the regulatory review and approval process;
- our inability to effectively protect our intellectual property;
- costs associated with future litigation and the outcome of such litigation;
- our inability to attract and retain key personnel;
- our inability to obtain additional financing, reduce expenses or generate funds when necessary; and
- adverse economic and political conditions.

In addition, you should refer to the "Risk Factors" sections of this report and of our Annual Report on Form 10-K for the year ended December 31, 2018 for a discussion of other factors that may cause our actual results to differ materially from those described by our forward-looking statements. As a result of these factors, we cannot assure you that the forward-looking statements contained in this report will prove to be accurate and, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material.

We encourage readers of this report to understand forward-looking statements to be strategic objectives rather than absolute targets of future performance. Forward-looking statements speak only as of the date they are made. We do not intend to update publicly any forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made or to reflect the occurrence of unanticipated events except as required by law. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, if at all.

The following discussion and analysis, the purpose of which is to provide investors and others with information that we believe to be necessary for an understanding of our financial condition, changes in financial condition and results of operations, should be read in conjunction with the financial statements, notes thereto and other information contained in this report.

## Company Overview



Antares Pharma, Inc. (“Antares,” “we,” “our,” “us” or the “Company”) is a combination drug device company focused primarily on the development and commercialization of self-administered parenteral pharmaceutical products and technologies. Our strategy is to identify new or existing approved drug formulations and apply our patented drug delivery technology to enhance the drug delivery methods. We develop, manufacture and commercialize, for ourselves or with partners, novel therapeutic products using our advanced drug delivery systems that are designed to provide commercial or functional advantages, such as improved safety and efficacy,

18

---

reduced side effects, and enhanced patient comfort and adherence. Our intramuscular and subcutaneous injection technology platforms include the VIBEX® and VIBEX® QuickShot® pressure-assisted auto injector systems suitable for branded and generic injectable drugs in unit dose containers as well as disposable multi-dose pen injectors. We have a portfolio of proprietary and partnered commercial products and ongoing product development programs in various stages of development. We have formed significant strategic alliances and partnership arrangements with industry leading pharmaceutical companies including Teva, AMAG and Pfizer.

We developed and commercialized XYOSTED™ (testosterone enanthate) injection, indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone, which was approved by the FDA on September 28, 2018 and launched for commercial sale in November 2018. XYOSTED™ is the only FDA approved subcutaneous testosterone enanthate product for once-weekly, at-home self-administration. In connection with the launch of XYOSTED™, we hired approximately 50 additional sales representatives and cross-trained the combined sales force to leverage our existing resources and enhance our commercial organization. Our sales representatives started detailing XYOSTED™ to physicians in the second half of December 2018.

We market and sell our proprietary product OTREXUP® (methotrexate) injection, which is a subcutaneous methotrexate injection for once weekly self-administration with an easy-to-use, single dose, disposable auto injector, indicated for adults with severe active rheumatoid arthritis, children with active polyarticular juvenile idiopathic arthritis and adults with severe recalcitrant psoriasis.

Through our commercialization partner Teva, we sell Sumatriptan Injection USP indicated in the U.S. for the acute treatment of migraine and cluster headache in adults. We received FDA approval of our Abbreviated New Drug Application (“ANDA”) for 4 mg/0.5 mL and 6 mg/0.5 mL single-dose prefilled syringe auto-injectors, a generic equivalent to Imitrex® STATdose Pen®. Sumatriptan Injection USP is the Company’s first ANDA approval of a complex generic and second product approved using the VIBEX® auto injector platform.

We developed and supply a variation of our VIBEX® QuickShot® subcutaneous auto injector for use with AMAG’s progestin hormone drug Makena® (hydroxyprogesterone caproate injection) under an exclusive license and development agreement. The Makena® subcutaneous auto injector drug-device combination product is a ready-to-administer treatment indicated to help reduce the risk of preterm birth in women pregnant with one baby and who spontaneously delivered one preterm baby in the past, which was approved by the FDA in February 2018. We are the exclusive supplier of the devices and the final assembled and packaged commercial product, which was launched in the U.S. for commercial sale by AMAG in March 2018, and we receive royalties on AMAG’s net sales of the product.

In collaboration with Teva, we developed a version of our VIBEX® auto injector for use in a generic epinephrine auto injector product that was approved by the FDA in August 2018 and commercially launched in limited quantities in late fourth quarter of 2018. Teva’s Epinephrine Injection USP is indicated for emergency treatment of severe allergic reactions including those that are life threatening (anaphylaxis) in adults and certain pediatric patients and was approved as a generic drug product with an AB rating, meaning that it is therapeutically equivalent to Mylan, Inc.’s branded products EpiPen® and EpiPen Jr® and therefore, subject to state law, substitutable at the pharmacy. We are the exclusive supplier of the device and Teva is responsible for commercialization and distribution of the finished product, for which we also receive royalties on Teva’s net sales.

We are also collaborating with Teva on a multi-dose pen for a generic form of BYETTA® (exenatide injection) for the treatment of type 2 diabetes, and another multi-dose pen for a generic form of Forteo® (teriparatide [rDNA origin] injection) for the treatment of osteoporosis. Teva continues to work through the regulatory process with the FDA for exenatide and teriparatide using the ANDA pathway. Teva and Eli Lilly and Company (“Lilly”) settled their Paragraph

IV patent litigation related to Teva's ANDA for teriparatide, the terms of which have not been disclosed. Teva also successfully completed a decentralized procedure registration process in 17 countries in Europe for teriparatide, and is awaiting patent clearance in the EU prior to launch.

In August 2018, we entered into a collaboration agreement with Pfizer to develop a combination drug device rescue pen. This rescue pen will utilize the Antares QuickShot® auto injector and an undisclosed Pfizer drug. We will develop the product and Pfizer will be responsible for obtaining FDA approval of the combination product. We intend to enter into a separate supply agreement with Pfizer pursuant to which we will provide fully packaged commercial ready finished product to Pfizer and Pfizer will then be responsible for commercializing the product in the U.S., pending FDA approval, for which the Company will receive royalties on net sales.

We also make reusable, needle-free injection devices that administer injectable drugs, which are currently marketed primarily through Ferring and JCR Pharmaceuticals CO., Ltd., for use with human growth hormone. However, in October 2017, we entered into an asset purchase agreement (the "Asset Purchase Agreement") with Ferring (the "Ferring Transaction") to sell the worldwide rights, including certain assets, related to the needle-free auto injector device product line for a total purchase price of \$14.5 million, of which

the final installment of \$5.0 million is payable to us upon Ferring's receipt of the CE Mark needed to continue to commercialize the needle-free product in certain territories and the final transfer of certain product-related inventory, equipment and agreements to Ferring (the "Completion Date".) We will continue to manufacture and supply needle-free devices and receive payment for devices and a royalty on net product sales in accordance with the existing license and supply agreements until the Completion Date, which we expect to occur in 2019.

## Results of Operations

We reported net losses of \$5.5 million and \$6.2 million for the three months ended March 31, 2019 and 2018, respectively. Net loss per share was \$0.03 for the three months ended March 31, 2019 as compared to \$0.04 for the three months ended March 31, 2018. Operating results for the three months ended March 31, 2019 are not necessarily indicative of the results that may be expected for the year ending December 31, 2019. The following is an analysis and discussion of our operations for the three months ended March 31, 2019 as compared to the same period in 2018.

## Revenues

We generate revenue from proprietary and partnered product sales, license and development activities and royalty arrangements. Total revenue for the three months ended March 31, 2019 and 2018 was \$23.3 million and \$12.7 million, respectively, representing an increase in total revenue of 83% on a comparative basis. The following table provides details about the components of our revenue (in thousands):

|                                   | Three months<br>ended March 31, |          |
|-----------------------------------|---------------------------------|----------|
|                                   | 2019                            | 2018     |
| Proprietary product sales         | \$4,771                         | \$3,971  |
| Partnered product sales           | 13,529                          | 6,978    |
| Total product revenue             | 18,300                          | 10,949   |
| Licensing and development revenue | 915                             | 1,285    |
| Royalties                         | 4,071                           | 469      |
| Total revenue                     | \$23,286                        | \$12,703 |

## Product Revenue

Total revenue from product sales was \$18.3 million and \$10.9 million for the three months ended March 31, 2019 and 2018, respectively, an increase of 67% on a period over period basis. The increase in product revenue was driven primarily by sales of recently approved products, both proprietary and partnered, as discussed below.

For the three months ended March 31, 2019 and 2018, we recognized revenue of \$4.8 million and \$4.0 million, respectively, from sales of our proprietary products OTREXUP® and XYOSTED™, which is presented net of estimated product returns and sales allowances. The increase in proprietary product sales for the three months ended March 31, 2019 as compared to the three months ended March 31, 2018 was principally attributable to sales of XYOSTED™, which was launched for commercial sale in late 2018.

Partnered product sales were \$13.5 million and \$7.0 million for the three months ended March 31, 2019 and 2018, respectively. We manufacture and sell devices, components and fully assembled and packaged product to our partners Teva, AMAG and Ferring. The increase in sales of partnered products for the three months ended March 31, 2019 as

compared to the same period in 2018 is primarily attributable to sales of auto injector devices sold to Teva for use with their Epinephrine Injection USP, and an increase in sales of Sumatriptan Injection USP to Teva and needle-free devices to Ferring. We will continue to manufacture and supply needle-free devices through the completion of the Ferring Transaction, which is expected to occur in 2019.

#### Licensing and development revenue

Licensing and development revenue include license fees received from partners for the right to use our intellectual property and amounts earned in joint development arrangements with partners under which we perform joint development activities or develop new products on their behalf. Licensing and development revenue was \$0.9 million and \$1.3 million for the three months ended March 31, 2019 and 2018, respectively. The decrease in development revenue recognized for the three months ended March 31, 2019 as compared to 2018 was primarily a result of a reduction in development activities with AMAG related to the Makena<sup>®</sup> auto injector product. As discussed above, we have ongoing development programs with Pfizer and Teva.

## Royalties

Royalty revenue was \$4.1 million and \$0.5 million for the three months ended March 31, 2019 and 2018, respectively. The significant increase in royalty revenue was primarily attributable to royalties received from AMAG on their net sales of the Makena® subcutaneous auto injector. A portion of the increase was also attributable to royalties received from Teva on their net sales of Epinephrine Injection USP, which was launched in late 2018.

## Cost of Revenue and Gross Profit

The following table summarizes our total revenue, cost of revenue and gross profit (in thousands):

|                         | Three months<br>ended March 31, |          |
|-------------------------|---------------------------------|----------|
|                         | 2019                            | 2018     |
| Total revenue           | \$23,286                        | \$12,703 |
| Total cost of revenue   | 10,946                          | 7,186    |
| Gross profit            | \$12,340                        | \$5,517  |
| Gross profit percentage | 53 %                            | 43 %     |

Fluctuations in our gross profit and gross profit percentage are driven by our overall revenue mix. Our gross profit was \$12.3 million and \$5.5 million for the three months ended March 31, 2019 and 2018, respectively. The increase in our gross profit and gross profit percentage was primarily attributable to the significant increase in royalty revenue, which have no associated incremental cost. Other variations in cost of revenue and gross profit were attributable to our increase in product revenue, and to our development activities, which fluctuate depending on the mix of development projects in progress and stages of completion in each period.

## Research and Development Expenses

Research and development expenses consist of external costs for clinical studies and analysis activities, design work and prototype development, FDA application fees, personnel costs and other general operating expenses associated with our research and development activities. Research and development expenses were \$2.4 million and \$2.9 million for the three months ended March 31, 2019 and 2018, respectively. The decrease in research and development costs on a comparative basis was primarily due to higher spending associated with XYOSTED™ prior to its approval in 2018.

## Selling, General and Administrative Expenses

Selling, general and administrative expenses were \$14.9 million and \$8.2 million for three months ended March 31, 2019 and 2018, respectively. The increase in selling, general and administrative expenses was principally attributable to incremental sales and marketing costs incurred in connection with the recent launch of XYOSTED™, including the increase in compensation and benefits expense associated with approximately 50 additional sales representatives hired in late 2018.

## Liquidity and Capital Resources

At March 31, 2019, we had cash and cash equivalents of \$23.2 million. Our principal liquidity needs are to fund our product manufacturing, research and development activities and for the payment of other operating expenses. We have not historically generated, and do not currently expect to generate, enough revenue or operating cash flow to support or grow our operations and we continue to operate primarily by raising capital. Our primary sources of liquidity are proceeds from equity offerings and debt issuance. We believe that the combination of our current cash and cash equivalents, projected product sales, development revenue milestones and royalties will provide us with sufficient funds to meet our obligations and support operations through at least the next twelve months from the date of this report.

#### At the Market Common Stock Offering Program

We are party to a sales agreement (the “Sales Agreement”) with Cowen and Company, LLC (“Cowen”) under which we may offer and sell, from time to time at our sole discretion, shares of common stock having an aggregate offering price of up to \$30.0 million through Cowen as our sales agent and/or principal. Cowen may sell the common stock by any method permitted by law deemed to be an “at the market offering” (the “Offering”) as defined in Rule 415 of the Securities Act of 1933, as amended. We pay Cowen a commission of 3.0% of the gross sales proceeds of any common stock sold through Cowen under the Sales Agreement.

During the three months ended March 31, 2019, we sold 2.3 million shares of common stock pursuant to the Offering and Sales Agreement, which generated gross proceeds of \$8.1 million less sales commission and payment of offering costs, resulting in net offering proceeds to the Company of \$7.8 million. To date, we have sold 4.4 million shares pursuant to the Offering with an aggregate offering price of \$15.6 million.

#### Net Cash Flows from Operating Activities

Operating cash inflows are generated primarily from product sales, license and development fees and royalties. Operating cash outflows consist principally of expenditures for manufacturing costs, personnel costs, general and administrative expenses, research and development projects, and sales and marketing activities. Fluctuations in cash used in operating activities are primarily a result of the timing of cash receipts and disbursements. Net cash used in operating activities was \$12.0 million for the three months ended March 31, 2019 and \$6.0 million for the three months ended March 31, 2018. The increase in net cash used in operating activities was primarily driven by our net loss, inventory build, growth in accounts receivable and other changes in operating assets and liabilities due to timing of cash receipts and cash payments.

#### Net Cash Flows from Investing Activities

Net cash used in investing activities was \$0.4 million for the three months ended March 31, 2019 as compared to net cash provided by investing activities of \$2.7 million for the three months ended March 31, 2018. The net cash outflow for the three months ended March 31, 2019 was solely attributable to capital expenditures as compared to the net cash inflow for the three months ended March 31, 2018 which included the receipt of \$2.75 million in connection with the Ferring Transaction offset by payments for capital expenditures and patent acquisition costs.

#### Net Cash Flows from Financing Activities

The net cash flow provided by financing activities was \$7.7 million for the three months ended March 31, 2019, and consisted of \$7.8 million in cash proceeds received from sales of our common stock and \$0.3 million proceeds from the exercise of stock options offset by \$0.4 million remitted to taxing authorities in connection with net-share settled awards for which we withheld shares equivalent to the value of the employees' tax obligation for the applicable income and other employment taxes. Net cash used in financing activities for the three months ended March 31, 2018 was \$0.1 million, which included proceeds received in connection with the exercise of stock options offset by amounts paid to taxing authorities for net-share settled equity awards.

#### Contractual Obligations

The following table presents our contractual obligations and the related payments, including interest, due by period as of March 31, 2019:

|                             | Payments Due by Period |                  |             |             |                   |
|-----------------------------|------------------------|------------------|-------------|-------------|-------------------|
|                             | Total                  | Less than 1 year | 1 - 3 years | 3 - 5 years | More than 5 years |
| Long-Term Debt Obligations  | \$30,774               | \$7,211          | \$19,220    | \$4,343     | \$ —              |
| Operating Lease Obligations | 2,023                  | 923              | 1,100       | —           | —                 |
| Total                       | \$32,797               | \$8,134          | \$20,320    | \$4,343     | \$ —              |



## Critical Accounting Policies and Use of Estimates

The preceding discussion and analysis of our results of operations and financial condition is based upon our consolidated financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). The preparation of these consolidated financial statements requires us to make judgments and estimates that affect the reported amounts of assets, liabilities, revenues and expenses. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances. Actual results could differ from our estimates, and significant variances could materially impact our financial condition and results of operations.

The accounting policies we believe to be most critical to understanding our results of operations and financial condition related to revenue recognition and inventory valuation, which are fully described in our Annual Report on Form 10-K for the year ended December 31, 2018.

#### Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements, including any arrangements with any structured finance, special purpose or variable interest entities.

#### Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Our primary market risk exposure is foreign exchange rate fluctuations of the Swiss Franc to the U.S. dollar as the financial position and operating results of our subsidiaries in Switzerland are translated into U.S. dollars for consolidation. Our exposure to foreign exchange rate fluctuations also arises from transferring funds to our Swiss subsidiaries in Swiss Francs. In addition, we have exposure to exchange rate fluctuations between the Euro and the U.S. dollar. We do not currently use derivative financial instruments to hedge against exchange rate risk. The effect of foreign exchange rate fluctuations on our financial results for the period ended March 31, 2019 was not material.

We may be exposed to interest rate risk and interest rate fluctuations as a result of our long-term debt financing. Our loan, with a current outstanding principal balance of \$25.0 million accrues interest at a calculated prime-based variable rate with a maximum interest rate of 9.50%, which was the rate in effect during the three months ended March 31, 2019. A hypothetical increase or decrease in the interest rate of 1.0% would result in additional or lower incremental annual interest expense of \$250,000.

#### Item 4. CONTROLS AND PROCEDURES

##### Disclosure Controls and Procedures

The Company's management, under the supervision and with the participation of the Company's Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the Company's disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended) as of the end of the period covered by this report. The evaluation was performed to determine whether the Company's disclosure controls and procedures have been designed and are functioning effectively to provide reasonable assurance that the information required to be disclosed by the Company in reports filed under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission's rules and is accumulated and communicated to management, including the Company's principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Based on such evaluation, the Company's Chief Executive Officer and Chief Financial Officer have concluded that the Company's disclosure controls and procedures as of the end of the period covered by this report were effective.

##### Internal Control over Financial Reporting

There have not been any changes in the Company's internal control over financial reporting during the fiscal quarter to which this report relates that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting other than additional controls that were designed and implemented in connection with the adoption of Accounting Standards Update No. 2016-02, Leases (Topic 842).

A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. The design of any system of controls is also based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, control may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of the inherent

limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

## PART II - OTHER INFORMATION

### Item 1. LEGAL PROCEEDINGS

On October 23, 2017, Randy Smith filed a complaint in the District of New Jersey, captioned Randy Smith, Individually and on Behalf of All Others Similarly Situated v. Antares Pharma, Inc., Robert F. Apple and Fred M. Powell (“Smith”), Case No. 3:17-cv-08945-MAS-DEA, on behalf of a putative class of persons who purchased or otherwise acquired Antares securities between December 21, 2016 and October 12, 2017, inclusive, asserting claims for purported violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 against Antares, Robert F. Apple and Fred M. Powell. The Smith complaint contends that defendants made false and/or misleading statements and/or failed to disclose that: (i) Antares had provided insufficient data to the FDA in connection with the NDA for XYOSTED™; and (ii) accordingly, Antares had overstated the approval prospects for XYOSTED™. On July 27, 2018, the court entered an order appointing Serghei Lungu as lead plaintiff, Pomerantz LLP as lead counsel, and Lite DePalma Greenberg, LLC as liaison counsel for plaintiff. On August 3, 2018, the parties submitted a stipulation and proposed order, setting forth an agreed-upon schedule for responding to the complaint, which the court granted. Pursuant to that order, plaintiff filed a Consolidated Amended Class Action Complaint on October 9, 2018. On November 26, 2018, defendants filed a motion to dismiss. Plaintiff filed an opposition to the motion on January 10, 2019 and defendants filed a reply in support of their motion on February 25, 2019. The Company believes that the claims in the Smith action lack merit and intends to defend them vigorously.

On January 12, 2018, a stockholder of our Company filed a derivative civil action, captioned Chiru Mackert, derivatively on behalf of Antares Pharma, Inc., v. Robert F. Apple, et al. (“Mackert”), in the Superior Court of New Jersey Chancery Division, Mercer County (Case No. C-000011-18). On January 17, 2018, another stockholder filed a derivative action in the same court, captioned Vikram Rao, Derivatively on Behalf of Antares Pharma, Inc. v. Robert F. Apple, et al. (“Rao”) (Case No. C-000004-18). Both complaints name Robert F. Apple, Fred M. Powell, Thomas J. Garrity, Jacques Gonella, Anton Gueth, Leonard S. Jacob, Marvin Samson and Robert P. Roche, Jr. as defendants, and the Company as nominal defendant, and they assert claims for breach of fiduciary duties, unjust enrichment, abuse of control, gross mismanagement, and waste of corporate assets arising from the same facts underlying the Smith securities class action. The plaintiffs seek damages, corporate governance and internal procedure reforms and improvements, restitution, reasonable attorneys’ fees, experts’ fees, costs, and expenses. The parties have filed a stipulation consolidating the two actions and staying the proceedings pending the court’s decision on defendants’ motion to dismiss the Smith action.

On January 17, 2018, a stockholder of our Company filed a derivative civil action, captioned Robert Clark, Derivatively on Behalf of Antares Pharma, Inc. v. Robert F. Apple, et al. (“Clark”) (Case No. 3:18-cv-00703-MAS-DEA), against Robert F. Apple, Thomas J. Garrity, Jacques Gonella, Leonard S. Jacob, Marvin Samson, Anton G. Gueth and Robert P. Roche, Jr. as defendants, and Company as a nominal defendant. The action was filed in the U.S. District Court for the District of New Jersey and asserts claims for breach of fiduciary duties, unjust enrichment, abuse of control, waste of corporate assets, and a violation of Section 14(a) of the Securities Exchange Act of 1934. This complaint relates to the same facts underlying the Smith securities class action and the other derivative actions. The plaintiff in Clark seeks damages, corporate governance and internal procedure reforms and improvements, reasonable attorneys’ fees, accountants’ and experts’ fees, costs, and expenses. The parties have filed a stipulation staying the action pending the court’s decision on defendants’ motion to dismiss the Smith action.

### Item 1A. RISK FACTORS

In addition to the information contained in this report, you should carefully consider the risk factors discussed in Part I, “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2018, which could materially affect our business, financial condition or future results. The risks described in our Annual Report on Form 10-K are not the only risks we face. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and/or operating results.

Item 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS  
None.

Item 3. DEFAULT UPON SENIOR SECURITIES  
None.

Item 4. MINE SAFETY DISCLOSURES  
Not applicable.

Item 5. OTHER INFORMATION  
None.

24

---

Item 6. EXHIBITS

(a) Exhibit Index

| Exhibit No. | Description  |
|-------------|--|
| 31.1#       | <u>Certificate of the Chief Executive Officer of Antares Pharma, Inc. required by Rule 13a-14(a) under the Securities Exchange Act of 1934, as amended, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</u> |
| 31.2#       | <u>Certificate of the Chief Financial Officer of Antares Pharma, Inc. required by Rule 13a-14(a) under the Securities Exchange Act of 1934, as amended, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</u> |
| 32.1##      | <u>Certificate of the Chief Executive Officer of Antares Pharma, Inc. required by Rule 13a-14(b) under the Securities Exchange Act of 1934, as amended, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</u> |
| 32.2##      | <u>Certificate of the Chief Financial Officer of Antares Pharma, Inc. required by Rule 13a-14(b) under the Securities Exchange Act of 1934, as amended, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</u> |
| 101.INS#    | XBRL Instance Document   |
| 101.SCH#    | XBRL Taxonomy Extension Schema Document  |
| 101.CAL#    | XBRL Taxonomy Extension Calculation Linkbase Document  |
| 101.LAB#    | XBRL Taxonomy Extension Label Linkbase Document  |
| 101.PRE#    | XBRL Taxonomy Extension Presentation Linkbase Document   |
| 101.DEF#    | XBRL Taxonomy Extension Definition Document  |

# Filed herewith.

##Furnished herewith.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

ANTARES PHARMA, INC.

May 2, 2019 /s/ Robert F. Apple  
Robert F. Apple  
President and Chief Executive Officer  
(Principal Executive Officer)

May 2, 2019 /s/ Fred M. Powell  
Fred M. Powell  
Executive Vice President and Chief Financial Officer  
(Principal Financial and Accounting Officer)